Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report
Abstract Background Tocilizumab has been shown to be effective for treatment of juvenile idiopathic arthritis (JIA). To our knowledge, this is the first reported case of interstitial lung disease occurring shortly after tocilizumab infusion in a patient with JIA. Case presentation A 14-year-old fema...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13223-021-00594-7 |
id |
doaj-937ed8e2af614fd69fac419dd6756152 |
---|---|
record_format |
Article |
spelling |
doaj-937ed8e2af614fd69fac419dd67561522021-09-12T11:49:22ZengBMCAllergy, Asthma & Clinical Immunology1710-14922021-09-011711710.1186/s13223-021-00594-7Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case reportKoichi Sugihara0Risa Wakiya1Hiromi Shimada2Mikiya Kato3Tomohiro Kameda4Shusaku Nakashima5Mai Mahmoud Fahmy Mansour6Yusuke Ushio7Norimitsu Kadowaki8Hiroaki Dobashi9Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityDivision of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa UniversityAbstract Background Tocilizumab has been shown to be effective for treatment of juvenile idiopathic arthritis (JIA). To our knowledge, this is the first reported case of interstitial lung disease occurring shortly after tocilizumab infusion in a patient with JIA. Case presentation A 14-year-old female patient with polyarticular JIA developed interstitial lung disease after intravenous and subcutaneous administration of tocilizumab. Her condition improved with glucocorticoid therapy. Conclusion Our results suggest that increased interleukin-6 levels in the blood following tocilizumab treatment may be linked to development of interstitial lung disease.https://doi.org/10.1186/s13223-021-00594-7Juvenile idiopathic arthritisDrug-induced interstitial lung diseaseTocilizumabInterleukin-6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Koichi Sugihara Risa Wakiya Hiromi Shimada Mikiya Kato Tomohiro Kameda Shusaku Nakashima Mai Mahmoud Fahmy Mansour Yusuke Ushio Norimitsu Kadowaki Hiroaki Dobashi |
spellingShingle |
Koichi Sugihara Risa Wakiya Hiromi Shimada Mikiya Kato Tomohiro Kameda Shusaku Nakashima Mai Mahmoud Fahmy Mansour Yusuke Ushio Norimitsu Kadowaki Hiroaki Dobashi Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report Allergy, Asthma & Clinical Immunology Juvenile idiopathic arthritis Drug-induced interstitial lung disease Tocilizumab Interleukin-6 |
author_facet |
Koichi Sugihara Risa Wakiya Hiromi Shimada Mikiya Kato Tomohiro Kameda Shusaku Nakashima Mai Mahmoud Fahmy Mansour Yusuke Ushio Norimitsu Kadowaki Hiroaki Dobashi |
author_sort |
Koichi Sugihara |
title |
Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report |
title_short |
Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report |
title_full |
Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report |
title_fullStr |
Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report |
title_full_unstemmed |
Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report |
title_sort |
interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report |
publisher |
BMC |
series |
Allergy, Asthma & Clinical Immunology |
issn |
1710-1492 |
publishDate |
2021-09-01 |
description |
Abstract Background Tocilizumab has been shown to be effective for treatment of juvenile idiopathic arthritis (JIA). To our knowledge, this is the first reported case of interstitial lung disease occurring shortly after tocilizumab infusion in a patient with JIA. Case presentation A 14-year-old female patient with polyarticular JIA developed interstitial lung disease after intravenous and subcutaneous administration of tocilizumab. Her condition improved with glucocorticoid therapy. Conclusion Our results suggest that increased interleukin-6 levels in the blood following tocilizumab treatment may be linked to development of interstitial lung disease. |
topic |
Juvenile idiopathic arthritis Drug-induced interstitial lung disease Tocilizumab Interleukin-6 |
url |
https://doi.org/10.1186/s13223-021-00594-7 |
work_keys_str_mv |
AT koichisugihara interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT risawakiya interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT hiromishimada interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT mikiyakato interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT tomohirokameda interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT shusakunakashima interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT maimahmoudfahmymansour interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT yusukeushio interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT norimitsukadowaki interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport AT hiroakidobashi interstitiallungdiseaseoccurringshortlyaftertocilizumabinfusioninapatientwithpolyarticularjuvenileidiopathicarthritisacasereport |
_version_ |
1717755355180564480 |